PL2628746T3 - Sposób zatężania polipeptydu - Google Patents

Sposób zatężania polipeptydu

Info

Publication number
PL2628746T3
PL2628746T3 PL13167427T PL13167427T PL2628746T3 PL 2628746 T3 PL2628746 T3 PL 2628746T3 PL 13167427 T PL13167427 T PL 13167427T PL 13167427 T PL13167427 T PL 13167427T PL 2628746 T3 PL2628746 T3 PL 2628746T3
Authority
PL
Poland
Prior art keywords
polypeptide
concentration
Prior art date
Application number
PL13167427T
Other languages
English (en)
Polish (pl)
Inventor
Stefan Nilsson
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL2628746T3 publication Critical patent/PL2628746T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL13167427T 2006-04-04 2007-04-04 Sposób zatężania polipeptydu PL2628746T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
PCT/DK2007/000177 WO2007112757A2 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
EP08166902.0A EP2100898B1 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
EP07711305.8A EP2004672B1 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
EP13167427.7A EP2628746B1 (en) 2006-04-04 2007-04-04 A process for the concentration of a polypeptide

Publications (1)

Publication Number Publication Date
PL2628746T3 true PL2628746T3 (pl) 2019-07-31

Family

ID=38472949

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13167428.5T PL2631242T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu
PL08166902T PL2100898T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu
PL13167427T PL2628746T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL13167428.5T PL2631242T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu
PL08166902T PL2100898T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu

Country Status (20)

Country Link
US (6) US20090246187A1 (enExample)
EP (4) EP2631242B1 (enExample)
JP (6) JP2009532394A (enExample)
KR (3) KR20150103339A (enExample)
CN (1) CN105233276A (enExample)
AU (2) AU2007234195B2 (enExample)
BR (1) BRPI0709737A2 (enExample)
CA (3) CA2644642C (enExample)
DK (1) DK2628746T3 (enExample)
ES (3) ES2713488T3 (enExample)
HU (1) HUE042402T2 (enExample)
IL (4) IL194267A (enExample)
MX (1) MX2008012748A (enExample)
NO (3) NO347673B1 (enExample)
NZ (7) NZ607595A (enExample)
PL (3) PL2631242T3 (enExample)
PT (1) PT2628746T (enExample)
SI (1) SI2628746T1 (enExample)
WO (1) WO2007112757A2 (enExample)
ZA (2) ZA200805346B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
NO347673B1 (no) * 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.
CN102834111B (zh) 2010-02-24 2014-11-12 齐姆内克斯公司 用于生产和纯化重组溶酶体α-甘露糖苷酶的方法
RS61683B1 (sr) 2010-06-25 2021-05-31 Shire Human Genetic Therapies Isporuka terapijskih agenasa u centralni nervni sistem
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
BR112012033197A2 (pt) 2010-06-25 2017-06-06 Shire Human Genetic Therapies métodos e composições para liberação de cns de n-sulfatase de heparano.
MX344795B (es) * 2010-06-25 2017-01-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a.
WO2013009686A2 (en) 2011-07-08 2013-01-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
ES2751369T3 (es) * 2012-11-13 2020-03-31 Chiesi Farm Spa Purificación de galactocerebrósido beta-galactosidasa humana recombinante (galchr)
CA2893609A1 (en) * 2012-12-11 2014-06-19 Centogene Ag Method for the diagnosis of metachromatic leukodystrophy
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
CN111065735B (zh) 2017-08-31 2023-07-07 株式会社绿十字 用于纯化硫酸酯酶蛋白的方法
KR102290596B1 (ko) 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
EP1049487B1 (en) 1998-01-27 2002-05-22 Hemebiotech A/S Treatment of acute intermittent porphyria (aip) and other porphyric diseases
US6281336B1 (en) * 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
PL196770B1 (pl) * 1998-06-09 2008-01-31 Statens Seruminstitut Sposób oczyszczania immunoglobuliny, produkt immunoglobuliny i jego zastosowanie
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
CA2378373C (en) * 1999-07-27 2011-12-13 Hemebiotech A/S Production of rhpbgd and new therapeutic methods for treating patients with acute intermittent porphyria (aip) and other porphyric diseases
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
WO2003002731A1 (en) 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
EP2399586A1 (en) 2002-01-11 2011-12-28 Jefferies, Dr., Wilfred Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) * 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
EP2532742B1 (en) * 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
SI1740204T1 (en) * 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
NO347673B1 (no) * 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.

Also Published As

Publication number Publication date
KR101504969B1 (ko) 2015-03-24
KR20090018894A (ko) 2009-02-24
CA2644642C (en) 2016-01-26
JP2009273469A (ja) 2009-11-26
EP2100898B1 (en) 2019-06-19
JP5384232B2 (ja) 2014-01-08
ES2713488T3 (es) 2019-05-22
IL194267A0 (en) 2011-08-01
EP2004672A2 (en) 2008-12-24
EP2628746B1 (en) 2019-01-09
PL2100898T3 (pl) 2019-11-29
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
NZ597548A (en) 2013-08-30
WO2007112757A3 (en) 2008-02-28
IL235982A0 (en) 2015-01-29
NZ582045A (en) 2011-07-29
PT2628746T (pt) 2019-04-23
NO347673B1 (no) 2024-02-19
NO20211305A1 (no) 2008-10-31
CA2632528A1 (en) 2007-10-11
NZ588903A (en) 2012-08-31
DK2628746T3 (en) 2019-04-01
AU2008229659B2 (en) 2013-01-31
NO20082510L (no) 2008-10-31
CA2632528C (en) 2022-07-12
BRPI0709737A2 (pt) 2011-07-26
CA2644642A1 (en) 2007-10-11
US20170202927A1 (en) 2017-07-20
US9713634B2 (en) 2017-07-25
JP2013236633A (ja) 2013-11-28
AU2007234195A1 (en) 2007-10-11
CA2882501C (en) 2021-09-07
KR20140057678A (ko) 2014-05-13
US20120076767A1 (en) 2012-03-29
JP2014058521A (ja) 2014-04-03
US20140314735A1 (en) 2014-10-23
US20090246187A1 (en) 2009-10-01
IL241654B (en) 2019-02-28
NZ607595A (en) 2014-10-31
JP2014051503A (ja) 2014-03-20
CA2882501A1 (en) 2007-10-11
AU2007234195B2 (en) 2013-02-07
NO20084776L (no) 2008-10-31
JP2016104000A (ja) 2016-06-09
WO2007112757A2 (en) 2007-10-11
EP2628746A3 (en) 2014-03-19
NZ623123A (en) 2015-04-24
US20180289777A1 (en) 2018-10-11
JP2009532394A (ja) 2009-09-10
ES2744499T3 (es) 2020-02-25
EP2631242A2 (en) 2013-08-28
JP5878152B2 (ja) 2016-03-08
NZ571610A (en) 2011-07-29
EP2631242A3 (en) 2013-10-02
EP2631242B1 (en) 2022-08-03
IL211905A0 (en) 2011-05-31
KR20150103339A (ko) 2015-09-09
ES2928096T3 (es) 2022-11-15
IL194267A (en) 2015-10-29
EP2628746A2 (en) 2013-08-21
ZA200805346B (en) 2018-11-28
IL241654A0 (en) 2015-11-30
EP2100898A1 (en) 2009-09-16
NO346368B1 (no) 2022-06-27
US20160193304A1 (en) 2016-07-07
AU2008229659A1 (en) 2008-10-23
PL2631242T3 (pl) 2023-03-20
SI2628746T1 (sl) 2019-04-30
CN105233276A (zh) 2016-01-13
ZA200809540B (en) 2019-09-25
NZ568728A (en) 2011-09-30
EP2004672B1 (en) 2015-08-19
HUE042402T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
PL2628746T3 (pl) Sposób zatężania polipeptydu
ZA200900836B (en) Process for the purification of FC-fusion proteins
PL1903019T3 (pl) Sposób wytwarzania izoolefin
GB0619941D0 (en) Chemical process
GB0619942D0 (en) Chemical process
GB0607394D0 (en) Process
GB0600914D0 (en) Process
GB0604874D0 (en) Process
PL1700855T3 (pl) Sposób wytwarzania tazarotenu
GB0604233D0 (en) Process
GB2471802B (en) Chemical process
ZA200905055B (en) Method for the production of benzofuran-2-carboxamides
GB0606283D0 (en) Process
HK1120274A (en) A process for concentration of a polypeptide
GB2471803B (en) Chemical process
IL181944A0 (en) A process for the concentration of hcl
GB0618832D0 (en) Chemical process
GB201017988D0 (en) Chemical process
GB0603232D0 (en) Process
PL381076A1 (pl) Sposób wytwarzania polimetylenomoczników
PL380878A1 (pl) Sposób wytwarzania biohumusu
GB0615035D0 (en) Process for the production of lime
HU0600838D0 (en) Chemical process
GB0625907D0 (en) Chemical process
GB0624147D0 (en) Chemical process